Global Hypertension Drug Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Hypertension Drug Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Hypertension, as a chronic disease, requires patients to take medicine for a long time to control their blood pressure. Hypertension drug is a kind of drug that can control blood pressure and treat hypertension. It can avoid the damage of target organs such as heart, brain and kidney caused by long-term hypertension, and reduce the risk of major cardiovascular and cerebrovascular diseases such as cerebral stroke.

Market Overview:

The latest research study on the global Hypertension Drug market finds that the global Hypertension Drug market reached a value of USD 23594.34 million in 2022. It’s expected that the market will achieve USD 27218.36 million by 2028, exhibiting a CAGR of 2.41% during the forecast period.

Medical progress may replace the traditional hypertension drug

At present, the mainstream treatment of hypertension is still taking hypertension drug. For some patients with mild hypertension, conservative treatment, such as lifestyle intervention, can be considered to control blood pressure. Its purpose is to lower blood pressure and control other risk factors. The main measures include: reducing sodium salt intake and increasing potassium intake; Reasonable diet; Weight control; Do not smoke or drink; Increase exercise; Reduce mental stress and keep mood stable.

With the rapid development of medical science and technology, it is possible to get rid of drug treatment and intervene with instruments. Renal denervation (RDN) is a new technology. In recent years, the new instruments of RDN are constantly developing, which is expected to block the renal nerve more safely and reliably. Scientific research shows that RDN can safely and effectively treat untreated hypertension or mild to moderate hypertension. Some other antihypertensive therapies are still under study, and their clinical application prospects are still unclear, including: baroreflex activation therapy, carotid chemoreceptor ablation, deep brain stimulation and slow breathing therapy, etc.

The continuous development of medicine will give hypertensive patients more treatment options, and the possibility of hypertension drug being replaced will increase, and the hypertension drug industry may face certain challenges.

Market competition intensifies

With the expiration of the patents of original hypertension drugs, such as losartan/hydrochlorothiazide, losartan potassium/losartan potassium, and ipratropium mesylate, etc. After generic drugs went on the market at a lower price, the overall price of hypertension drugs was lowered, and the market competition became increasingly fierce.

Although the demand for hypertension drug is on the rise, the change of drug use structure (more generic drugs with lower prices are used instead of original research drugs) has a certain impact on market sales, but it is beneficial for generic drug manufacturers. The downward pressure on the product price of hypertension drug will gradually increase.

Region Overview:

Asia-Pacific dominated the Hypertension Drug market in 2022, with a market share of 43.42%.

Company Overview:

Novartis AG is one of the major players operating in the Hypertension Drug market, holding a share of 6.7% in 2022.

Novartis AG

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

AstraZeneca Plc

It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company's product portfolio includes biologics, prescription pharmaceuticals and vaccines.

Segmentation Overview:

By type, Calcium Channel Blockers segment accounted for the largest share of market in 2022.

Calcium Channel Blockers

Calcium channel blockers are medications used to lower blood pressure. They work by preventing calcium from entering the cells of the heart and arteries. Calcium causes the heart and arteries to squeeze (contract) more strongly. By blocking calcium, calcium channel blockers allow blood vessels to relax and open.

Diuretics

Diuretics, also called water pills, are a common treatment for high blood pressure. They reduce both systolic and diastolic blood pressures in the great majority of hypertensive patients. Diuretics administered alone or in combination with other agents form the basis of therapy for the majority of hypertensive patients.

Beta Blockers

Beta blockers, also known as beta-adrenergic blocking agents, are medications that reduce blood pressure. Beta blockers work by blocking the effects of the hormone epinephrine, also known as adrenaline.

Beta blockers cause the heart to beat more slowly and with less force, which lowers blood pressure. Beta blockers also help widen veins and arteries to improve blood flow.

Angiotensin Converting Enzyme Inhibitors

Angiotensin-converting enzyme inhibitors are medications that help relax the veins and arteries to lower blood pressure. ACE inhibitors prevent an enzyme in the body from producing angiotensin II, a substance that narrows blood vessels. This narrowing can cause high blood pressure and forces the heart to work harder. Angiotensin II also releases hormones that raise blood pressure.

Angiotensin-2 receptor blockers

Angiotensin II receptor blockers (ARBs) have similar effects as ACE inhibitors, another type of blood pressure drug, but work by a different mechanism. These drugs block the effect of angiotensin II, a chemical that narrows blood vessels. By doing so, they help widen blood vessels to allow blood to flow more easily, which lowers blood pressure. ARBs are generally prescribed for people who cannot tolerate ACE inhibitors.

Vasodilators

Vasodilators are medications that open (dilate) blood vessels. They affect the muscles in the walls of the arteries and veins, preventing the muscles from tightening and the walls from narrowing. As a result, blood flows more easily through the vessels. The heart doesn't have to pump as hard, reducing blood pressure.

Alpha Blockers

Alpha blockers are a type of blood pressure medication. They lower blood pressure by preventing a hormone called norepinephrine from tightening the muscles in the walls of smaller arteries and veins. As a result, the blood vessels remain open and relaxed. This improves blood flow and lowers blood pressure.

Application Overview:

The market's largest segment by application is the segment Hospital, with a market share of 52.09% in 2022.

Key Companies in the global Hypertension Drug market covered in Chapter 3:

Boehringer Ingelheim
Organon & Co.
Takeda Pharmaceutical Company
Bayer AG
Sanofi S.A
Daiichi Sankyo Company
AstraZeneca Plc
Lupin Limited
Viatris Inc.
Novartis AG

In Chapter 4 and Chapter 14.2, on the basis of types, the Hypertension Drug market from 2018 to 2029 is primarily split into:

Calcium Channel Blockers
Diuretics
Beta Blockers
Angiotensin Converting Enzyme Inhibitors
Angiotensin-2 receptor blockers
Vasodilators
Alpha Blockers
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Hypertension Drug market from 2018 to 2029 covers:

Hospital
Clinic
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)